<DOC>
	<DOCNO>NCT02928250</DOCNO>
	<brief_summary>Carnosine , naturally-occurring dipeptide ( β-alanyl-L-histidine ) first described 1900 Gulewitsch Amiradzibi , find predominantly post-mitotic tissue ( e.g . brain innervated muscle ) vertebrates . Carnosine claim decrease oxygen free-radical mediate damage cellular macromolecule either chelate divalent cation scavenge hydroxy radical imidazole moiety . Free-radical damage process affect structure proteins nucleic acid . To best knowledge , previous study assess role carnosine diabetes associate complication particular diabetic nephropathy insufficient evidence recommend supplementation patient . Therefore , study undertaken investigate role carnosine adjuvant therapy diabetic nephropathy child adolescent type 1 diabetes assess relation microalbuminuria , tubulointerstitial damage marker , glycemic control oxidative stress .</brief_summary>
	<brief_title>Role Carnosine Adjuvant Therapy Diabetic Nephropathy Pediatrics With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>patient type 1 diabetes . diabetic nephropathy ( ≤18 year least 5 year disease duration ) clinical evidence infection , renal impairment due cause diabetes , elevate liver enzyme , hypertension , neoplasm , hypersensitivity carnosine , take vitamin food supplement one month study participation previous investigational drug study within 30 day precede screening .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>